CDKN2A and pancreatic neoplasm: Interestingly, CDKN2A‐inactivated pancreatic cancer exhibits increased sensitivity to paclitaxel and irinotecan, with paclitaxel in particular mimicking the effects of CDKN2A restoration [18].